KR100783205B1 - The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity - Google Patents
The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity Download PDFInfo
- Publication number
- KR100783205B1 KR100783205B1 KR1020060086952A KR20060086952A KR100783205B1 KR 100783205 B1 KR100783205 B1 KR 100783205B1 KR 1020060086952 A KR1020060086952 A KR 1020060086952A KR 20060086952 A KR20060086952 A KR 20060086952A KR 100783205 B1 KR100783205 B1 KR 100783205B1
- Authority
- KR
- South Korea
- Prior art keywords
- cold water
- mushroom
- water extract
- polysaccharide fraction
- crude polysaccharide
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 60
- 150000004676 glycans Chemical class 0.000 title claims abstract description 48
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 48
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title abstract description 10
- 241000222355 Trametes versicolor Species 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 230000003908 liver function Effects 0.000 claims abstract description 10
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 52
- 210000004905 finger nail Anatomy 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 208000019423 liver disease Diseases 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000002401 inhibitory effect Effects 0.000 description 15
- 231100000304 hepatotoxicity Toxicity 0.000 description 13
- 206010019851 Hepatotoxicity Diseases 0.000 description 11
- 235000015872 dietary supplement Nutrition 0.000 description 11
- 230000007686 hepatotoxicity Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 108010062580 Concanavalin A Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 231100000334 hepatotoxic Toxicity 0.000 description 4
- 230000003082 hepatotoxic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 108010001062 polysaccharide-K Proteins 0.000 description 3
- 229940034049 polysaccharide-k Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010073976 UDP-GlcNAc-undecaprenyl phosphate N-acetylglucosaminyl 1-phosphate transferase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- -1 glycerin fatty acid ester Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000002420 orchard Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
도 1은 운지버섯 냉수추출물의 제조방법에 대한 순서도이다.1 is a flow chart for the manufacturing method of fingertips cold water extract.
도 2는 운지버섯 조다당 분획물의 제조방법에 대한 순서도이다.2 is a flowchart illustrating a method for preparing a fingernail crude polysaccharide fraction.
도 3은 운지버섯 냉수추출물 및 운지버섯 조다당 분획물의 항산화 활성 효과를 나타내는 그래프이다.Figure 3 is a graph showing the antioxidant activity effect of the fingerlings cold water extract and fingerlings crude polysaccharide fraction.
도 4는 운지버섯 냉수추출물 및 운지버섯 조다당 분획물의 간독성 억제효과를 나타내는 그래프이다.Figure 4 is a graph showing the hepatotoxicity inhibitory effect of the fingerlings cold water extract and fingerlings crude polysaccharide fraction.
도 5는 운지버섯 냉수추출물 및 운지버섯 조다당 분획물의 간독성 억제활성의 최적의 농도를 나타내는 그래프이다.5 is a graph showing the optimal concentration of hepatotoxicity inhibitory activity of the fingerling cold water extract and fingering crude polysaccharide fraction.
도 6은 운지버섯 냉수추출물 및 운지버섯 조다당 분획물을 함유하는 조성물의 간독성 억제효과를 나타내는 그래프이다.Figure 6 is a graph showing the hepatotoxicity inhibitory effect of the composition containing the fingerling cold water extract and fingering mushroom copolysaccharide fraction.
본 발명은 항산화 활성과 간기능 개선 효능을 갖는 운지버섯 냉수추출물 및 운지버섯 조다당 분획물을 유효성분으로 함유하는 약학 조성물 및 건강기능식품에 관한 것이다.The present invention relates to a pharmaceutical composition and a dietary supplement comprising the fingering cold water extract and fingering crude polysaccharide fraction having an antioxidant activity and improving liver function as an active ingredient.
최근 환경의 오염과 새로운 감염병과 면역질환의 확산 그리고 노인인구의 증가 등에 따라 각종 질환의 유병율이 증가하는 추세에 있으며, 그 중에서도 40대 중반부터 발생 빈도가 높은 성인병 및 퇴행성 질환의 증가는 대단히 높은 상태이다. 특히 한국에 있어서는 식생활문화의 특성과 사회생활에서의 스트레스, 음주와 흡연과 같은 요인들에 의해 대사성 질환과 심혈관계 질환이 크게 증가하고 있다.In recent years, the prevalence of various diseases has increased due to environmental pollution, the spread of new infectious diseases and immune diseases, and the increase of the elderly population. Among them, the increase in the number of adult and degenerative diseases, which frequently occur from the mid-40s, is very high. to be. Especially in Korea, metabolic and cardiovascular diseases are increasing due to the characteristics of dietary culture, stress in social life, drinking and smoking.
한국의 경우에 있어서 단일 질병으로 보면 여러 부위에서 발생하는 암이 가장 중요한 질병으로 지목되지만, 점차로 심장병이나 뇌졸중과 같은 심혈관계 질환은 물론 간질환, 당뇨병, 비만과 같은 대사성 질환도 점차 심각한 질병군으로 대두되고 있다. 한편 경제발전에 따른 생활수준의 향상에 의해 개인이 갖는 건강에 대한 관심은 급속히 높아지고 있으며, 특히 심혈관계 및 대사성 질환과 같은 성인병의 관리에 관련해서도 각종 건강 유지법, 스포츠 요법, 건강식품 및 건강보조식품, 예방차원의 의약품 등 예방 및 치료를 위한 많은 방법들이 이용되고 있다. In Korea, cancer that occurs in multiple areas is the most important disease in Korea, but cardiovascular diseases such as heart disease and stroke, as well as metabolic diseases such as liver disease, diabetes, and obesity are becoming more serious diseases. It is becoming. On the other hand, due to the improvement of living standards according to the economic development, the interest in the health of the individual is rapidly increasing, especially in the management of adult diseases such as cardiovascular and metabolic diseases, various health maintenance methods, sports therapy, health foods and health supplements Many methods are used for prevention and treatment, such as food and preventive medicines.
간질환은 선천성 요인, 바이러스 감염, 화학물질에 의한 노출 등이 원인이 되어 발생하는 질병으로, 다량의 알콜섭취에 의한 일시적이며 급성인 간 손상과 같은 증 상을 비롯하여 B형 간염과 같은 만성적인 질환까지 다양하게 발병한다. 특히 간질환은 지방간, 간경화, 간암 등의 증상을 동반하게 되는 경우가 있는데, 이들 증상에 의해 위험한 결과를 초래할 수 있다. 또한 간질환은 간조직의 기능저하에 의해 기타 다른 조직의 기능에도 부정적인 영향을 미치게 되어 영양상태의 불균형은 물론 혈관계 질환과 경우에 따라서는 기저질환의 악화 등을 초래하게 된다.Liver disease is caused by congenital factors, viral infections, or exposure to chemicals. Chronic diseases such as hepatitis B, including symptoms such as temporary and acute liver damage caused by high alcohol intake. Various outbreaks In particular, liver disease may be accompanied by symptoms such as fatty liver, cirrhosis of the liver, liver cancer, and these symptoms may cause dangerous consequences. In addition, liver disease negatively affects the function of other tissues due to deterioration of liver tissue, resulting in malnutrition, vascular disease and in some cases worsening of underlying disease.
간질환의 발병기전에는 여러 가지 복잡한 작용이 관련되어 있으나, 바이러스나 화학물질과 같은 외인성 요인 혹은 스트레스와 같은 내인성 요인에 의해 간세포 내에서 발생하는 산화작용이 커다란 원인이 되는 것으로 알려져 있다. 따라서 항산화활성이 높은 물질을 섭취함으로서, 간세포의 기능을 높여주어 간질환을 억제하고자 하는 수많은 시도가 이루어져 왔다. 항산화 작용을 통해 간기능을 개선하고 간질환을 치료하기 위한 식품 혹은 의약품 소재로서 가장 많이 이용되어 온 것은 플라보노이드 계통의 화합물을 다량으로 함유하는 식물 추출물과 버섯류이다. 이들 소재들 중에서는 민간요법에서 간기능을 향상시키기 위한 목적으로 사용되고 있는 것도 있으나, 아직은 과학적 근거가 부족하고 효능이 불안정하여 실제로 이용되는 예는 그다지 많지 않다.The pathogenesis of liver disease is associated with a number of complex actions, but it is known that oxidative action in liver cells is caused by exogenous factors such as viruses and chemicals or by endogenous factors such as stress. Therefore, by ingesting a substance with high antioxidant activity, many attempts have been made to suppress liver disease by enhancing the function of hepatocytes. The most widely used food or pharmaceutical ingredients for improving liver function and treating liver disease through antioxidant activity are plant extracts and mushrooms containing a large amount of compounds of flavonoid family. Some of these materials are used for the purpose of improving liver function in folk remedies, but there are not many examples that are actually used due to lack of scientific evidence and unstable efficacy.
운지버섯(Coriolus versicolor)은 구멍장이과에 속하는 버섯으로 구름버섯이라 불리기도 하는데, 침엽수와 광엽수의 죽은 나무, 혹은 그루터기에서 자라나는 원형 및 반원형의 흑색 혹은 회색의 버섯이다. 운지버섯은 항암작용을 지니는 것으로 잘 알려져 있으며, 특히 항암작용에 관련하는 기능성 성분은 이 버섯의 세포벽을 이루 는 물질인 글루칸(glucan)이며 흔히 폴리사카라이드-케이(Polysaccharide-K; PSK)라 불린다. 이 PSK는 정상세포에는 거의 독성이 없고, 암세포에 대하여 특이적인 독성을 나타내며, 또한 면역세포를 활성화시키는 효능이 있는 것으로 알려져 있다. 한편 운지버섯이 만성 기관지염, 관상 순환장애, 위궤양, 만성 간장염, 관절염, 고혈압 등에 효과가 있는 것으로 알려져 있으나, 아직 과학적인 근거가 제시된 자료는 거의 전무한 상태이다.Coriolus versicolor is a fungus belonging to the orchard family, also called a cloud mushroom. It is a round and semicircular black or gray mushroom that grows on dead trees of coniferous and broad-leaved trees or stumps. Cloud finger mushrooms are well known for their anti-cancer activity. Especially, the functional component related to anti-cancer activity is glucan, a substance that forms the cell wall of the mushroom, and is often called polysaccharide-K (PSK). . This PSK is known to be almost nontoxic to normal cells, to show specific toxicity to cancer cells, and to activate immune cells. On the other hand, it is known that the fingering mushrooms are effective in chronic bronchitis, coronary circulation disorder, gastric ulcer, chronic hepatitis, arthritis, hypertension, but there is almost no scientific evidence.
이에 본 발명자들은 운지버섯의 냉수추출물과 운지버섯의 조다당 분획물이 높은 항산화 효과와 간독성에 대한 억제효과를 가지는 것을 발견하여, 이 운지버섯 냉수추출물과 운지버섯 조다당 분획물 성분을 함유하는 조성물이 간세포의 독성을 완화하고 간기능을 개선시킬 수 있음을 발견하고 본 발명을 완성하였다.Accordingly, the inventors have found that the cold water extract of the fingerling mushroom and the crude polysaccharide fraction of the fingerling mushroom have a high antioxidant effect and the inhibitory effect on hepatotoxicity, and the composition containing the components of the fingernail cold water extract and the fingernail crude polysaccharide fraction is liver cells. The present invention was found to be able to alleviate the toxicity and to improve liver function.
본 발명은 항산화 활성과 간기능 개선 효능을 갖는 운지버섯 냉수추출물 및 운지버섯의 조다당 분획물을 유효성분으로 함유하는 약학 조성물 및 건강기능식품을 제공하는 것을 목적으로 한다.It is an object of the present invention to provide a pharmaceutical composition and a dietary supplement comprising a finger extract of cold finger mushrooms having a antioxidant activity and an effect of improving liver function, and a crude polysaccharide fraction of fingertip mushrooms as an active ingredient.
상기의 목적을 달성하기 위하여, 본 발명은 운지버섯 냉수추출물 및 운지버섯의 조다당 분획물을 유효성분으로 하고 약제학적으로 허용 가능한 담체, 부형제 또는 희석재를 포함하는 항산화 활성과 간기능 개선 효능을 갖는 약학 조성물을 제공한다.In order to achieve the above object, the present invention has an anti-oxidant activity and liver function-improving effect, including a finger extract of cold finger mushroom and crude polysaccharide fraction of finger finger mushroom as an active ingredient and a pharmaceutically acceptable carrier, excipient or diluent It provides a pharmaceutical composition.
또한, 본 발명은 운지버섯 냉수추출물 및 운지버섯의 조다당 분획물을 유효성분으로 하고 식품학적으로 허용 가능한 식품보조 첨가제를 포함하는 항산화 활성과 간기능 개선 효능을 갖는 건강기능식품을 제공한다.In addition, the present invention provides a dietary supplement having antioxidant activity and liver function-improving effect including the fingerling cold water extract and the crude polysaccharide fraction of the fingerling as an active ingredient and a food supplement acceptable food supplement.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 운지버섯 냉수추출물은 운지버섯을 수세하여 자연 탈수시킨 후 세절하고 중량에 대해 7배량의 멸균 증류수를 넣어 4℃의 온도에서 72시간 동안 냉수 추출한 후, 원심분리에 의해 얻어진 상청액을 여과지(0.45 μm filter paper)로 여과하여 동결 건조시킨 무균상태의 운지버섯 냉수추출물을 수득한다(도1 참조).The cold finger mushroom extract of the present invention is washed with water and then naturally dehydrated by washing the fingerling mushroom, and then sterile distilled water of 7 times by weight is added to extract cold water at a temperature of 4 ° C. for 72 hours, and the supernatant obtained by centrifugation is filtered through a filter paper ( 0.45 μm filter paper) was filtered to obtain sterile cold fingerling cold water extract (see FIG. 1).
한편, 운지버섯의 조다당 분획물은 수세, 탈수 및 세절한 운지버섯에 20배량의 멸균증류수를 넣고, 부피가 최초 부피의 30%가 되도록 유지하면서 100℃에서 3시간 가열처리하고 여과지를 통해 추출액을 여과한다. 이 추출액에 최초 부피와 동량이 되도록 에탄올(95%)을 혼합하여 4℃에서 12시간 방치하고, 원심분리를 통해 침전물(조다당 분획)을 얻는다. 이 침전물을 멸균증류수로 녹인 후, 80℃에서 에탄올 냄새가 없어질 때까지 가열함으로서 에탄올을 제거한다. 에탄올이 제거된 분획을 동결 건조하여 운지버섯 조다당 분획물을 수득한다(도 2참조).On the other hand, the crude polysaccharide fraction of the fingering mushroom is put into 20 times of sterile distilled water in the washed, dehydrated and shredded fingerling mushrooms, heat-treated at 100 ℃ for 3 hours while maintaining the volume to 30% of the original volume, and extract the extract through filter paper Filtered. Ethanol (95%) was mixed in the extract to the same volume and left to stand at 4 ° C for 12 hours, to obtain a precipitate (copolysaccharide fraction) through centrifugation. The precipitate is dissolved in sterile distilled water and then heated to 80 ° C. until no ethanol odor is removed to remove ethanol. The fraction from which ethanol was removed was freeze-dried to obtain a fingerling crude polysaccharide fraction (see FIG. 2).
상기 본 발명의 운지버섯 냉수추출물 및 운지버섯의 조다당 분획물을 유효성분으로 하는 약학 조성물은 약학적 조성물의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석재를 더 포함 할 수 있다.The pharmaceutical composition comprising the finger extract of the present invention and the crude polysaccharide fraction of the finger finger mushroom may further comprise appropriate carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.
본 발명에 따른 운지버섯 냉수추출물 및 운지버섯 조다당 분획물을 유효성분으로 하는 약학적 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액 등의 경구 형태로 제형화 하여 사용할 수 있다. 상기 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석재로는 락토오스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨 등을 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 습윤제, 결합제 등의 희석재 또는 부형제를 사용하여 제조한다.The pharmaceutical composition comprising the fingering cold water extract and fingering mushroom copolysaccharide fraction according to the present invention can be used in the form of oral forms, such as powders, granules, tablets, capsules, suspensions. Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, and the like. When formulated, it is prepared using diluents or excipients such as fillers, extenders, wetting agents, and binders.
본 발명의 약학적 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택할 수 있다. 바람직하게는 1일 5 mg/kg을 투여하는 것이 좋다. 투여횟수는 하루에 한번 투여 할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로도 본 발명의 범위를 한정하는 것은 아니다.Preferred dosages of the pharmaceutical compositions of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and can be appropriately selected by those skilled in the art. Preferably, 5 mg / kg is administered daily. The frequency of administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
또한, 상기 운지버섯 냉수추출물 및 운지버섯 조다당 분획물을 유효성분으로 하는 건강기능식품은 식품학적으로 허용 가능한 식품보조 첨가제를 더 포함할 수 있다.In addition, the functional food containing the fingertips cold water extract and fingering mushroom copolysaccharide fraction may further comprise a food supplement acceptable food supplement.
본 발명의 운지버섯 냉수추출물 및 운지버섯 조다당 분획물을 첨가할 수 있는 식 품으로는 음료, 차, 비타민 복합제, 건강보조식품류 등이 있으며, 환제, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용될 수 있다.The foods to which the fingerlings of the present invention can be added to the cold water extract and the fingerlings of the crude polysaccharide fraction include drinks, tea, vitamin complexes, health supplements, etc., in the form of pills, powders, granules, tablets, capsules or beverages. Can be used.
이하에서는 본 발명을 실시예에 따라 구체적으로 설명하는 바, 하기의 실시예는 본 발명을 설명하기 위하여 제시하는 것으로 본 발명이 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples. The following Examples are presented to explain the present invention, but the present invention is not limited thereto.
<실시예 1><Example 1>
운지버섯 냉수 추출물의 제조Preparation of fingerling mushroom cold water extract
운지버섯 500g을 수세하여 자연 탈수시킨 후 일정한 크기로 세절하고 3.5ℓ의 멸균 증류수를 넣어 4℃의 온도에서 72시간 동안 냉수 추출한 후, 원심분리에 의해 얻어진 상청액을 여과지(0.45 μm filter paper)로 여과하여 동결 건조 처리하여 55g의 무균상태의 운지버섯 냉수추출물을 얻었다.500 g of fingerling mushrooms were washed with water and dehydrated in a certain size. The mixture was rinsed to a certain size, and 3.5 liter of sterile distilled water was added. Cold water was extracted at a temperature of 4 ° C. for 72 hours, and the supernatant obtained by centrifugation was filtered with a filter paper (0.45 μm filter paper). The freeze-drying process was carried out to obtain 55g of aseptic mushroom cold water extract.
운지버섯 조다당 분획물의 제조Preparation of Crude Mushroom Polysaccharide Fractions
수세, 탈수 및 세절한 운지버섯 500g에 10ℓ의 멸균증류수를 넣고, 부피가 최초 부피의 30%가 되도록 유지하면서 100℃에서 3시간 가열처리하고 여과지(0.45 μm filter paper)를 통해 추출액을 여과한 다음, 이 추출액에 최초 부피와 동량이 되도록 7ℓ의 에탄올(95%)을 혼합하여 4℃에서 12시간 방치하고, 원심분리를 통해 침전물(조다당 분획)을 얻었다. 이 침전물을 250g의 멸균증류수로 녹인 후, 80℃에서 에탄올 냄새가 없어질 때까지 가열함으로서 에탄올을 제거하였다. 에탄올이 제거된 분획을 동결 건조하여 10g의 운지버섯 조다당 분획물을 얻었다.10 g of sterile distilled water was added to 500 g of washed, dehydrated and shredded fingernail mushrooms, heated at 100 ° C. for 3 hours while maintaining the volume at 30% of the original volume, and the extract was filtered through a filter paper (0.45 μm filter paper). To the extract, 7 liters of ethanol (95%) were mixed in the same volume and left to stand at 4 ° C for 12 hours, to obtain a precipitate (crude polysaccharide) through centrifugation. The precipitate was dissolved in 250 g of sterile distilled water and then heated to 80 ° C. until no ethanol odor was removed to remove ethanol. The ethanol-free fractions were freeze-dried to obtain 10 g of the fingerling crude polysaccharide fraction.
<실시예2>Example 2
캡슐제의 제조 Preparation of Capsule
실시예1에서 얻은 운지버섯 냉수추출물 0.05g, 운지버섯 조다당 분획물 0.05g, 결정성 셀룰로오스 0.03g, 락토오스 0.015g, 마그네슘 스테아레이트 0.005g을 통상의 캡슐제 제조방법에 따라 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.0.05 g of the finger finger mushroom cold water extract obtained in Example 1, 0.05 g of finger finger mushroom crude polysaccharide fraction, 0.03 g of crystalline cellulose, 0.015 g of lactose, 0.005 g of magnesium stearate were mixed according to a conventional capsule preparation method and filled into gelatin capsules. To prepare a capsule.
정제의 제조Manufacture of tablets
실시예1에서 얻은 운지버섯 물 추출물 0.05g, 운지버섯 조다당 분획물 0.05g, 옥수수전분 0.03g, 유당 0.01g, 정제수 0.005g, 스테아린산 마그네슘 0.005g을 통상의 정제 제조방법에 따라 타정하여 정제를 제조한다.The tablets were prepared by tableting 0.05g of the fingerling mushroom water extract obtained in Example 1, 0.05g of the fingerling mushroom polysaccharide fraction, 0.03g of corn starch, 0.01g of lactose, 0.005g of purified water, and 0.005g of magnesium stearate according to a conventional tablet preparation method. do.
액제의 제조Preparation of liquid
실시예1에서 얻은 운지버섯 물 추출물 0.15g, 운지버섯 조다당 분획물 0.15g, 이성화당 0.005g, 만니톨 0.005g, 정제수 100g을 통상의 액제 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시켜 전체 100ml로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.0.15 g of fingertip mushroom water extract obtained in Example 1, 0.15g of fingernail crude polysaccharide fraction, 0.005g of isomerized sugar, 0.005g of mannitol, and 100g of purified water were added to each component in purified water according to a conventional liquid preparation to dissolve the total 100ml. After adjusting to fill the brown bottle sterilized to prepare a liquid.
<실시예3>Example 3
건강보조식품의 제조Manufacturing of dietary supplements
실시예1에서 얻은 운지버섯 물 추출물 0.15g, 운지버섯 조다당 분획물 0.15g, 산화아연 0.002g, 산화마그네슘 0.005g, 스테아린산마그네슘 0.005g, 비타민 0.01mg, 글리세린지방산에스테르 0.005g를 통상의 건강식품 제조방법에 따라 혼합한 다음, 통상의 방법에 따라 건강보조식품을 제조한다.0.15 g of finger finger mushroom water extract obtained in Example 1, 0.15 g of finger finger mushroom crude polysaccharide fraction, zinc oxide 0.002 g, magnesium oxide 0.005 g, magnesium stearate 0.005 g, vitamin 0.01 mg, glycerin fatty acid ester 0.005 g After mixing according to the method, to prepare a dietary supplement according to a conventional method.
건강음료의 제조Manufacture of health drinks
실시예1에서 얻은 운지버섯 물 추출물 0.15g, 운지버섯 조다당 분획물 0.15g, 구연산 0.05g, 올리고당 0.05g, 타우린 0.05g, 매실농축액 0.002g, 정제수 100g 통상의 건강음료 제조방법에 따라 혼합한 다음, 2시간 동안 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 0.5리터 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The fingerling mushroom water extract obtained in Example 1 0.15g, the fingerling crude polysaccharide fraction 0.15g, citric acid 0.05g, oligosaccharide 0.05g, taurine 0.05g, plum concentrate 0.002g, purified water 100g after mixing according to the conventional healthy beverage manufacturing method After stirring and heating for 2 hours, the resulting solution is filtered and obtained in a sterilized 0.5-liter container, sealed and sterilized, and then refrigerated and then used in the manufacture of a healthy beverage composition of the present invention.
<실험예1>Experimental Example 1
운지버섯 냉수추출물과 운지버섯 조다당 분획물 각각의 항산화 활성측정Determination of Antioxidant Activity of Cold Water Extract of Fingerling Mushroom and Crude Polysaccharide Fraction of Fingering Mushroom
운지버섯의 냉수추출물과 운지버섯 조다당 분획물(다당체 추출물)의 항산화 활성을 확인하기 위하여 상기 실시예1에서 제조한 운지버섯의 냉수추출물과 운지버섯 조다당 분획물을 가지고 1,1-Diphenyl-2-picryhydarzyl(DPPH) 라디칼(Rradical) 소거활성을 측정하는 생체 외(In vitro)실헙법에서 측정하였다. DPPH는 그 자체가 매 우 안정한 자유 라디칼(free radical)로서 517 nm에서 특정적인 광흡수를 나타내는 보라색 화합물이다. DPPH 용액 (1.5 ⅹ 10-4M) 1 ml와 실시예1에서 제조한 운지버섯 냉수추출물, 운지버섯 조다당 분획물을 각각 0.1 ml 씩 섞은 후 30분간 방치한 다음 517 nm에서의 광흡수도 감소 정도를 조사하였다. 이 실험에서는 양성대조군으로서 BHT(butylated hydroxytoluene)를 사용하였다. 여러 농도의 운지버섯 냉수추출물과 운지버섯 조다당 분획물을 DPPH용액과 혼합하여 자유라디칼(free radical)의 소거활성을 측정하여 ED50 (50% effective dose)수치를 비교한 결과, 양성대조군인 BHT는 ED50가 약 12 mg/ml이었다. 한편 운지버섯 냉수추출물은 복합 추출물임에도 단일물질인 BHT와 거의 동등한 정도의 ED50수치를 나타내어, 높은 항산화 활성이 인정되었다. 한편 운지버섯 조다당 분획은 약 60 mg/ml의 ED50치를 나타내어, 운지버섯 냉수추출물 보다는 활성이 다소 낮기는 하지만, 항산화 활성을 지지는 것으로 나타났다. 이 실험결과로부터 운지버섯의 냉수추출물과 운지버섯 조다당 분획물은 일정 수준 이상의 높은 항산화 활성을 지니고 있음을 확인하였다. 그 결과를 도3에 나타내었다.In order to confirm the antioxidant activity of the cold water extract and the fingernail crude polysaccharide fraction (polysaccharide extract) of the fingerling mushroom, the cold water extract and the fingernail crude polysaccharide fraction of the fingertip mushroom prepared in Example 1 were used. picryhydarzyl (DPPH) radical scavenging activity was measured in vitro (In vitro) method to measure. DPPH is itself a very stable free radical, a purple compound that exhibits specific light absorption at 517 nm. 1 ml of DPPH solution (1.5 ⅹ 10 -4 M) and 0.1 ml of the finger finger mushroom cold water extract and finger finger coarse polysaccharide fractions prepared in Example 1 were mixed and left for 30 minutes, followed by a decrease in light absorption at 517 nm. Was investigated. In this experiment, BHT (butylated hydroxytoluene) was used as a positive control. By comparing the free radicals' scavenging activity by mixing the various concentrations of cold finger extracts and the finger polysaccharide fractions with DPPH solution, the ED 50 (50% effective dose) values were compared. ED 50 was about 12 mg / ml. On the other hand, even though the extract of the fingerlings cold water extract showed ED 50 values almost equivalent to BHT as a single substance, high antioxidant activity was recognized. On the other hand, the fingernail crude polysaccharide fraction had an ED 50 value of about 60 mg / ml. From the experimental results, it was confirmed that the cold water extract and the fingernail copolysaccharide fraction of the fingerling mushrooms had a certain level of high antioxidant activity. The results are shown in FIG.
<실험예 2>Experimental Example 2
운지버섯 냉수추출물과 운지버섯 조다당 분획물 각각의 경구투여에 의한 간독성 억제효과Hepatotoxicity Inhibitory Effects of Oral Mushroom Cold Water Extract and Fingernail Mushroom Polysaccharide Fraction
항산화 활성에서 유의한 효과가 확인된 운지버섯 냉수추출물과 운지버섯 조다당 분획물에 대하여 동물실험을 통한 간독성 억제효과를 검토하였다.The inhibitory effects of hepatotoxicity on the cold water extracts of the fingerlings and the crude polysaccharide fractions of the fingerlings, which were found to have significant effects on antioxidant activity, were examined.
암컷 Balb/c 마우스(8주령, 체중 21g)를 운지버섯 냉수추출물군, 운지버섯 조다당 분획물군, 대조군으로 각 군당 7마리씩 준비하고, 운지버섯 냉수추출물과 운지버섯 조다당 분획물을 각각 5 mg/mouse의 양으로 1일 1회씩 5일간 경구투여한 후에, 6일째에 Concanavalin-A(ConA)를 10 mg/kg의 양으로 정맥내 주사하여 간독성을 유발하였다. 간독성의 유발여부는 혈중에 함유된 GPT효소의 양을 측정키트(영동제약)를 이용하여 계측함으로서 판정하였다. 정상 마우스의 GPT치를 기준으로 상대적인 값을 계산하여 비교한 결과, ConA 투여 후 시간경과에 따라 GPT수치가 상승하다가 30시간째에는 GPT가 정상 대조군의 약 2.7배 이상의 수치를 나타내었다. 이와 같이 운지버섯 냉수추출물을 경구투여한 후에 ConA를 정맥주사한 마우스는 대조군에 비해 현저하게 높은 간독성 억제활성을 나타내었으며, 운지버섯 조다당 분획도 운지버섯 냉수추출물 보다는 낮지만 간독성을 억제하는 효과를 보였다. 그 결과를 도4에 나타내었다.Female Balb / c mice (8 weeks old, 21g body weight) were prepared for the fingering mushroom cold water extract group, fingerling mushroom copolysaccharide fraction group, and 7 rats for each group as a control group. Hepatotoxicity was induced by intravenous injection of Concanavalin-A (ConA) at a dose of 10 mg / kg on day 6 after oral administration of mice once daily for 5 days. The induction of hepatotoxicity was determined by measuring the amount of GPT enzyme in the blood using a measurement kit (Dongdo Pharmaceutical). As a result of comparing and calculating relative values based on the GPT values of the normal mice, GPT values increased with time after ConA administration, and at 30 hours, the GPT value was about 2.7 times higher than that of the normal control group. As a result, mice injected with ConA intravenously after the oral administration of cold finger mushroom extract showed significantly higher hepatotoxicity inhibitory activity compared to the control group, while the crude finger polysaccharide fraction of the fingerling mushroom was lower than that of the cold finger mushroom extract. Seemed. The results are shown in FIG.
<실험예3> Experimental Example 3
운지버섯 냉수추출물과 운지버섯 조다당 분획물 각각의 경구투여에 의한 간독성 억제활성의 최적농도 측정Optimal Concentration of Hepatotoxic Inhibitory Activity by Oral Administration of Cold Water Extract of Cloudfish and Crude Polysaccharide Fraction
운지버섯 냉수추출물과 운지버섯 조다당 분획물에 의한 간독성 억제효과에 대하여 최적 투여량을 조사하기 위하여 실험예2와 동일한 실험방법에 의해 운지버섯 냉 수추출물 및 운지벗서 조다당 분획물 각각의 투여량을 1∼10 mg/mouse의 범위에서 각각 5일간 경구투여하고, 다음날 ConA를 정맥주사한 후 30시간째의 혈청으로부터 GPT양을 측정하였다. 그 결과 운지버섯의 냉수추출물과 조다당 분획물은 공히 5 mg/mouse 이상의 양에서 간독성 억제효능이 변화가 없어, 5 mg/mouse의 투여량이 간독성 억제활성의 최적 조건인 것으로 확인되었다. 그 결과를 도5에 나타내었다.In order to investigate the optimal dose for the hepatotoxicity inhibitory effects of the fingerling cold water extract and the fingernail crude polysaccharide fraction, the dose of each of the cold finger mushroom extract and the fingerling crude polysaccharide fraction was Oral administration was performed for 5 days in the range of ˜10 mg / mouse, and the amount of GPT was measured from
<실험예4>Experimental Example 4
운지버섯 냉수추출물과 운지버섯 조다당 분획물을 함유하는 조성물의 간독성 억제효과Hepatotoxic Inhibitory Effects of the Compositions Containing Cold Water Extract of Cloudy Mushroom and Crude Polysaccharide Fraction of Cloudy Mushroom
운지버섯 냉수추출물과 운지버섯 조다당 분획물을 함유하는 조성물에 의한 간기능 개선효과를 극대화할 수 있는 운지버섯 냉수추출물과 운지버섯 조다당 분획물의 혼합비를 결정하기 위하여, 간독성에 대해 높은 억제효과를 나타내었던 운지버섯 냉수추출물 5 mg/mouse과 조다당 분획 5 mg/mouse를 혼합한 형태로 간독성에 대한 억제효과를 조사하였다. 상기 실험예2와 동일한 방법으로 동물실험을 행한 결과, 운지버섯 냉수추출물과 운지버섯 조다당 분획물을 각각 단독으로 투여하였을 때에 비해 이들 두 추출물을 혼합하여 투여하는 것이 보다 높은 시너지 효과를 유도하는 것으로 나타났다. 그 결과를 도6에 나타내었다.In order to determine the mixing ratio of the fingerling cold water extract and the fingerling crude polysaccharide fraction that can maximize the effect of improving liver function by the composition containing the fingerling cold water extract and the fingerling crude polysaccharide fraction, it shows a high inhibitory effect on liver toxicity. The inhibitory effect on hepatotoxicity was investigated in the form of a mixture of 5 mg / mouse of cold water extract and 5 mg / mouse of crude polysaccharide fraction. As a result of the animal experiment in the same manner as in Experiment 2, it was found that the administration of a mixture of these two extracts induces a higher synergy effect than when the cold finger mushroom cold water extract and the finger finger crude crude polysaccharide fraction were administered alone. . The results are shown in FIG.
<실험예5> Experimental Example 5
독성시험Toxicity Test
실시예1의 운지버섯 냉수추출물 및 운지버섯 조다당 분획물의 쥐에 대한 경구투여에 의한 독성 존재 유무를 조사하기 위하여 SD계통의 웅성 및 자성 쥐에 각각 1g/kg, 2g/kg 및 5g/kg 3개의 투여 용량으로 5마리씩 단회 경구투여하여 10일간의 사망예, 일반증상, 체중변화 및 부검소견을 관찰하였다. 그 결과 투여군 모두에서 시험 전기간 동안 사망예는 없었으며, 대조군에 비해 특이적으로 관찰된 일반증상의 변화도 없었다. 또한 체충변화 및 부검시 해부학적 소견에서도 특이한 증상은 거의 관찰되지 않았다.In order to investigate the presence or absence of the toxicity of the fingerlings of the fingerlings of the fingerlings and the fingerlings of the polysaccharide fraction of Example 1 by oral administration to rats, 1g / kg, 2g / kg and 5g / kg Five oral single doses of dogs were observed for 10 days of death, general symptoms, body weight change, and autopsy findings. As a result, there were no deaths during the entire test period in all the administration groups, and no change in general symptoms observed compared to the control group. In addition, few symptoms were observed in the anatomical findings at the time of wormworm and autopsy.
이상에서 설명한 바와 같이, 본 발명의 조성물은 우수한 항산화 활성으로 인하여 간 독성을 억제하여 간기능 개선에 탁월한 효과가 있어 간질환의 예방 및 치료용 약학적 조성물 및 건강기능식품으로 유용하게 사용할 수 있다.As described above, the composition of the present invention can be useful as a pharmaceutical composition and health functional food for the prevention and treatment of liver disease because it has an excellent effect on improving liver function by inhibiting liver toxicity due to excellent antioxidant activity.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060086952A KR100783205B1 (en) | 2006-09-08 | 2006-09-08 | The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060086952A KR100783205B1 (en) | 2006-09-08 | 2006-09-08 | The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100783205B1 true KR100783205B1 (en) | 2007-12-06 |
Family
ID=39140019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060086952A KR100783205B1 (en) | 2006-09-08 | 2006-09-08 | The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100783205B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104473284A (en) * | 2014-12-31 | 2015-04-01 | 华南师范大学 | Coriolus versicolor polysaccharide functional drink and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62174021A (en) * | 1985-10-14 | 1987-07-30 | Junko Matsubara | Antioxidant biophylactic agent |
KR20030029423A (en) * | 2001-10-08 | 2003-04-14 | 이정식 | Coriolus versicolor Mycellium beverage and Process for Preparing mycellium beverage |
KR20040069425A (en) * | 2003-01-29 | 2004-08-06 | 학교법인 영광학원 | Anti-complementary biopolymer from fruiting body of Coriolus versicolor and method for isolation thereof |
-
2006
- 2006-09-08 KR KR1020060086952A patent/KR100783205B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62174021A (en) * | 1985-10-14 | 1987-07-30 | Junko Matsubara | Antioxidant biophylactic agent |
KR20030029423A (en) * | 2001-10-08 | 2003-04-14 | 이정식 | Coriolus versicolor Mycellium beverage and Process for Preparing mycellium beverage |
KR20040069425A (en) * | 2003-01-29 | 2004-08-06 | 학교법인 영광학원 | Anti-complementary biopolymer from fruiting body of Coriolus versicolor and method for isolation thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104473284A (en) * | 2014-12-31 | 2015-04-01 | 华南师范大学 | Coriolus versicolor polysaccharide functional drink and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kreft | Buckwheat phenolic metabolites in health and disease | |
KR101501433B1 (en) | A composition for prevention and treatment of non-alcoholic fatty liver disease | |
KR102204299B1 (en) | Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component | |
KR101806474B1 (en) | A composition for improving, preventing and treating of bone diseases comprising Tenebrio molitor extract | |
KR101902911B1 (en) | Composition for improving human skin cell injury by UV-B comprising the extract of Hydrangea serrata | |
JP4413995B2 (en) | Medicinal plant extract with anti-obesity effect | |
KR102195547B1 (en) | Use of Cistanke Tubulosa Extract and Isoacteoside in Muscle Protection | |
TWI679985B (en) | Tie2 activator with olive fruit extract | |
KR20100042414A (en) | Composition for enhancing blood circulation containing the extract or fraction of prunus mume as an active ingredient | |
KR20160006812A (en) | Compositions for preventing and curing diabetes comprising extract of Paeonia lactiflora | |
KR100686260B1 (en) | Composition comprising the extract from melandryum firmum for improvement of liver function and treatment of liver diseases | |
KR100783205B1 (en) | The preparation containing coriolus versicolor extract and its polysaccharides having anti-hepatocytic activity | |
KR20130109495A (en) | Composition for preventing or treating renal disease | |
CN109925445A (en) | Anoectochilus causes the application in acute liver drug in preparation prevention and/or treatment D-Gal | |
KR101113603B1 (en) | Extract composition of herbal mixture for improving liver fucntion and relieving hangover | |
WO2008069604A1 (en) | Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease | |
KR20140108104A (en) | Compositions comprising the combined extract of Artemisia iwayomogi and Curcuma longa for treating, inhibiting or preventing obesity-related disease | |
KR101749674B1 (en) | Composition comprising Hericium erinaceum extract for prevent, treatment or improvement of inflammatory bone joint diseases | |
KR101529279B1 (en) | Liver cytoprotective composition comprising an extract of brassica juncea coss. and compounds isolated therefrom | |
KR101413771B1 (en) | A composition for anti-obesity comprising extract of big cone pine needle | |
KR101106376B1 (en) | A composition comprising the extract of dictyota coriacea treating and preventing neuro-degenerative disease | |
KR101899086B1 (en) | Composition for preventing, improving or treating liver damage | |
JP2005013123A (en) | Food composition | |
KR101892381B1 (en) | Composition for preventing or treating liver disease comprising pericarpium zanthoxyli extracts | |
KR20110115442A (en) | Composition for alcoholic hangover comprising clove |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120229 Year of fee payment: 5 |
|
LAPS | Lapse due to unpaid annual fee |